Clearside Biomedical Statistics Share Statistics Clearside Biomedical has 5.23M
shares outstanding. The number of shares has increased by 3.96%
in one year.
Shares Outstanding 5.23M Shares Change (YoY) 3.96% Shares Change (QoQ) 2.46% Owned by Institutions (%) 11.46% Shares Floating 4.54M Failed to Deliver (FTD) Shares 700 FTD / Avg. Volume 0.22%
Short Selling Information The latest short interest is 153.71K, so 2.94% of the outstanding
shares have been sold short.
Short Interest 153.71K Short % of Shares Out 2.94% Short % of Float 2.99% Short Ratio (days to cover) 2.08
Valuation Ratios The PE ratio is -2.04 and the forward
PE ratio is -0.91.
Clearside Biomedical's PEG ratio is
0.18.
PE Ratio -2.04 Forward PE -0.91 PS Ratio 42.14 Forward PS 6.2 PB Ratio -1.8 P/FCF Ratio -2.73 PEG Ratio 0.18
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Clearside Biomedical.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.44,
with a Debt / Equity ratio of -1.35.
Current Ratio 4.44 Quick Ratio 4.44 Debt / Equity -1.35 Debt / EBITDA -2.16 Debt / FCF -2.04 Interest Coverage -2.95
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $52K Profits Per Employee $-1.07M Employee Count 32 Asset Turnover 0.07 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -76.78% in the
last 52 weeks. The beta is 2.11, so Clearside Biomedical's
price volatility has been higher than the market average.
Beta 2.11 52-Week Price Change -76.78% 50-Day Moving Average 5.62 200-Day Moving Average 11.45 Relative Strength Index (RSI) 38.76 Average Volume (20 Days) 311,836
Income Statement In the last 12 months, Clearside Biomedical had revenue of 1.66M
and earned -34.35M
in profits. Earnings per share was -7.05.
Revenue 1.66M Gross Profit 1.51M Operating Income -28.88M Net Income -34.35M EBITDA -24.35M EBIT -24.57M Earnings Per Share (EPS) -7.05
Full Income Statement Balance Sheet The company has 20.02M in cash and 52.47M in
debt, giving a net cash position of -32.45M.
Cash & Cash Equivalents 20.02M Total Debt 52.47M Net Cash -32.45M Retained Earnings -355.27M Total Assets 15.33M Working Capital 8.74M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -24.7M
and capital expenditures -977K, giving a free cash flow of -25.68M.
Operating Cash Flow -24.7M Capital Expenditures -977K Free Cash Flow -25.68M FCF Per Share -5.22
Full Cash Flow Statement Margins Gross margin is 91.05%, with operating and profit margins of -1735.7% and -2064.42%.
Gross Margin 91.05% Operating Margin -1735.7% Pretax Margin -2064.42% Profit Margin -2064.42% EBITDA Margin -1463.16% EBIT Margin -1735.7% FCF Margin -1542.97%
Dividends & Yields CLSD does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CLSD is $75,
which is 1756.4% higher than the current price. The consensus rating is "Hold".
Price Target $75 Price Target Difference 1756.4% Analyst Consensus Hold Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 15, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Sep 15, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -36.36 Piotroski F-Score 2
